Does LIPC rs1800588 alter HDL size and large HDL particle levels?

The LIPC gene encodes hepatic lipase (HL), a key enzyme in lipoprotein metabolism. A common promoter variant, LIPC rs1800588 (-514C>T), directly regulates HL activity, initiating a cascade that alters HDL remodeling and particle size distribution.

Genetic and molecular mechanisms

• Transcription disruption: The rs1800588 T allele disrupts a CACGGC motif (an E-box-like site), weakening the binding of upstream stimulatory factors 1 and 2 (USF1/USF2).
• Reduced promoter activity: This disruption leads to a 20% to 30% reduction in LIPC promoter transcription in vitro.
• Dose-dependent enzyme reduction: In vivo, this translates to a gene-dose-dependent reduction in post-heparin plasma HL activity. Heterozygous (CT) individuals experience a 15% to 20% (~6 mmol/L·h) decrease, while homozygous (TT) individuals exhibit a 30% to 40% (~11 mmol/L·h) reduction compared to CC homozygotes.

HDL remodeling and particle size

• Enzymatic delipidation: Hepatic lipase serves as a dual triglyceride lipase and phospholipase, targeting large, buoyant, phospholipid-rich HDL2 particles.
• Size shifting: Active HL-mediated hydrolysis physically shrinks large HDL2 particles into smaller, denser HDL3 subclasses (7–9 nm) and remnant HDL.
• Subclass accumulation: Because HL activity drives this downsizing, lower HL activity in T allele carriers restricts the conversion of large HDL2 into smaller subclasses. This results in a pronounced accumulation of large HDL particles and a larger overall mean HDL size.

Bottom line

• The LIPC rs1800588 (T) variant impairs USF1/USF2 binding to reduce hepatic lipase activity in a gene-dose-dependent manner. This loss of enzymatic function prevents the normal breakdown and remodeling of large HDL2 particles, ultimately increasing overall HDL size and large HDL particle levels.